Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Key Points Eli Lilly’s stock price rose sharply as demand for its GLP-1 drugs increased. Novo Nordisk is…
Dr Simon Rose treats patients that others won’t touch. AHPRA wanted him gone
Doctor Simon Rose’s dusty ute rolls into Brewarrina in the golden hour of a late-November Sunday. He drives…
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Eli Lilly is the leader in the GLP-1 space, but here’s another GLP-1 stock and a medical device…
Subscribe to The Australian | Newspaper home delivery, website, iPad, iPhone & Android apps
The Australian Digital 12 Month Plan costs $416 (min. cost) for the first 12 months, charged as $32…
Gore teen tackles brain injury with positivity
Jayden Broome returned home to Gore two weeks ago after a four-month hospital stay. Jayden Broome loved playing…
Bed block blamed on aged care, NDIS support as NSW Health misses access targets
February 8, 2026 — 5:00am Save You have reached your maximum number of saved items. Remove items from…
Subscribe to The Australian | Newspaper home delivery, website, iPad, iPhone & Android apps
The Australian Digital 12 Month Plan costs $416 (min. cost) for the first 12 months, charged as $32…
As a medical specialist, I went to help alleviate suffering in Gaza — only to be denied entry
On 27 December 2025, I set off with three highly respected colleagues on flights to Amman, Jordan. All…
Oracle AI Healthcare Push And US$50b Raise Reshape Growth Outlook
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…
Patients, families suffer due to lack of transparency
Prof. Mayer Brezis has dedicated most of his professional life to preventing medical errors. A trained nephrologist, he…
2 Top Healthcare Stocks to Buy in February
There’s a bright future ahead for both, but it’s important to be patient. After underperforming broader equities over…
Boston Scientific’s shares tumble 18% despite strong FY25 growth
Boston’s growth was strong but investors evidently homed in on flat performance within the company’s cardiovascular portfolio. Image…